Promising Early Data from Cabaletta Bio’s Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment

Analyst Samantha Semenkow of Citi maintained a Buy rating on Cabaletta Bio, retaining the price target of $10.00.

Samantha Semenkow’s rating is based on promising early data from Cabaletta Bio’s trials involving their rese-cel therapy without lymphodepletion. The initial results from a small patient group with pemphigus vulgaris showed significant clinical improvements, as patients were able to discontinue immunomodulatory drugs while maintaining favorable safety profiles. The therapy’s cell expansion and persistence rates were comparable to those seen with lymphodepletion, suggesting a potential for broader application in autoimmune conditions.
Moreover, the elimination of lymphodepletion could simplify the CAR-T administration process and remove a significant bottleneck, potentially expanding the eligible patient population. The favorable safety outcomes, with minimal adverse effects, further support the potential of this therapy. Cabaletta Bio’s ongoing dose expansion efforts aim to confirm these early efficacy and safety signals, which could lead to a substantial increase in the stock’s value, as reflected in the high expected share price return.